TG Therapeutics Inc

XNAS:TGTX

37.94

-0.88 (-2.27%)

7:47:46 PM EDT: $38.00 +0.06 (+0.16%)

Market Cap (Intraday)	5.68B
Current PE	12.29
Forward PE	29.41
2yr Forward PE	14.88

See more stats

Estimates Current Quarter

Revenue	$226.55 Million
Adjusted EPS	$0.33

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

TG Therapeutics Inc Stock, XNAS:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560

United States of America

Phone: +1.212.554.4484

Number of Employees: 338

http://www.tgtherapeutics.com

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.